Skip to main content

Table 2 Multivariate analysis of CD8+PD-1+ double positive immune subsets with survival outcomes in patients with TNBC. Analysis was adjusted for tumor size, grade, age and lymph node status

From: Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer

Biomarkers HR 95% CI P-value
OS
 CD8+PD-1+ immune infiltrates
 High vs. low
0.56 0.29–1.06 0.073
 CD8+PD-1+ immune infiltrates
 High vs. low (adjusted for tumor size, grade, age and lymph node status and CD8+ total cell count)
0.77 0.35–1.67 0.510
DFS
 CD8+PD-1+ immune infiltrates
 High vs. low
0.47 0.28–0.80 0.006*
 CD8+PD-1+ immune infiltrates
 High vs. low (adjusted for tumor size, grade, age and lymph node status and CD8+ total cell count)
0.43 0.23–0.83 0.011*
  1. PD-1 programmed cell death protein-1, PD-L1 programmed cell death ligand 1
  2. *Statistically significant